StuartRichMD
Cardiology • Chicago, ILAdult Congenital Heart Disease, Heart Failure & Transplantation, Vascular Medicine
Director, Pulmonary Vascular Disease Program, Bluhm Cardiovascular Institute; Professor of Medicine, Northwestern University Feinberg School of Medicine
Dr. Rich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
675 N Saint Clair St
Chicago, IL 60611Phone+1 312-664-3278Fax+1 312-695-0063
Summary
- Stuart Rich, M.D., is Director of the Bluhm Cardiovascular Institute Pulmonary Vascular Disease Program, and Professor of Medicine at the Northwestern University Feinberg School of Medicine. Dr. Rich did is residency in medicine at Washington University in St. Louis, and fellowship in cardiology at the University of Chicago. Dr. Rich is one of the world’s most recognized experts on pulmonary vascular diseases. For more than 3 decades he has dedicated his research and clinical efforts to finding better solutions for pulmonary hypertension. His career began at the University of Illinois where he was PI for the NIH Registry on Primary Pulmonary Hypertension, and has been the leader of the largest clinical center in the U.S. for evaluating and treating patients with pulmonary hypertension since 1980. Dr. Rich has conducted pioneering research on the molecular mechanisms, epidemiology, clinical presentation, natural history and treatments of the disease. He has been a leader in the development of virtually every new treatment for pulmonary hypertension, as well as the use of therapeutic procedures and devices. His pioneering research has led to a greater understanding of all types of pulmonary hypertension.
Dr. Rich has been listed among the country’s top 1% of doctors by Castle Connolly Ltd. and Chicago magazine for more than 20 consecutive years. He has published hundreds of clinical articles and book chapters on pulmonary hypertension. In addition, he is Co-Founder of the Pulmonary Vascular Research Institute, a global health professional organization that is committed to bringing advances in treating pulmonary vascular diseases to the developing world. In 2014 he received the Heart for Hope Legacy Award from the Pulmonary Hypertension Association, in 2015 he received the Lifetime Achievement Award from the Pulmonary Vascular Research Institute, and in 2016 was designated as a "Living Legend" by the ACC.
Education & Training
University of ChicagoFellowship, Cardiovascular Disease, 1978 - 1980
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1975 - 1978
Loyola University Chicago Stritch School of MedicineClass of 1974
University of Illinois, College of Liberal Arts and SciencesB.S., General Biology, High Honors, 1967 - 1970- University of Illinois, College of Liberal Arts and SciencesB.S., Biology, High Honors, 1967 - 1970
University of ChicagoM.A., Biologic Sciences
Certifications & Licensure
IL State Medical License 1978 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Lifetime Achievement Award Pulmonary Vascular Research Institute, 2015
- Americas Top Doctors Castle Connolly, 2015
- Heart for Hope Legacy Award Pulmonary Hypertension Association, 2014
- Join now to see all
Clinical Trials
- Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization With Acute Vasodilator Testing Start of enrollment: 2010 May 01
- Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Exercise Testing Start of enrollment: 2010 May 01
- Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™. Start of enrollment: 2015 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 1879 citationsA Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionRobyn J. Barst, Lewis J. Rubin, Walker Long, Michael D. McGoon, Stuart Rich
The New England Journal of Medicine. 1996-02-01 - 125 citationsAnorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.Stuart Rich, Lewis J. Rubin, Alexander M. Walker, Sebastian Schneeweiss, Lucien Abenhaim
Chest. 2000-03-01 - 54 citationsEnhancing insights into pulmonary vascular disease through a precision medicine approach: A joint nhlbi-cardiovascular medical research and education fund workshop reportJohn H. Newman, Stuart Rich, Steven H. Abman, John H. Alexander, John Barnard
American Journal of Respiratory and Critical Care Medicine. 2017-06-15
Journal Articles
- Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertensionHemnes AR, Trammell AW, Archer SL, RICH S, Yu C, Nian H, Penner N, Funke M, Wheeler L, Robbins IM, Austin ED, Newman JH, West J, Circulation, 1/1/2015
- Pharmacological therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel reportTaichman D, Chung L, Klinger J, Lewis S, Mandel J, Ornelas J, Palevsky H, RICH S, Sood N, Trow T, Yung R, Elliott G, Badesch D, Chest, 1/1/2014
- Clinical diagnosis of pulmonary hypertensionRich JD, RICH S, Circulation, 1/1/2014
- Join now to see all
Books/Book Chapters
Other
- Primary Pulmonary Hypertension: Executive Summary from the World Symposium - Primary Pulmonary Hypertension 1998.RICH S (Eds), World Health Organization
http://web.archive.org/web/20020408173726/http://www.who.int/ncd/cvd/pph.html
1/1/1998 - Primary Pulmonary Hypertension: Executive Summary from the World Symposium – Primary Pulmonary Hypertension 1998.Rich S, editor, World Health Organization
http://web.archive.org/web/20020408173726/http://www.who.int/ncd/cvd/pph.html
1/1/1998 - Pulmonary hypertension and pulmonary embolism.Moser K, Resnekov L, RICH S, Cardiology Video Journal
1/1/1993 - Join now to see all
Press Mentions
Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)August 5th, 2021
Northwestern Medicine Cardiologist First in Illinois to Use Novel Treatment for Chronic Pulmonary EmbolismOctober 17th, 2018
Northwestern Medicine Receives Prestigious Pulmonary Hypertension Association AccreditationMarch 10th, 2017- Join now to see all
Committees
- Standing member, FDA Cardiovascular and Renal Drugs Advisory Committee 2013 - Present
Professional Memberships
- Fellow
- Fellow
- Fellow
- Fellow
External Links
- Bluhm Cardiovascular Institutehttp://pulmonaryhypertension.nm.org/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
